The benign prostate hyperplasia (BPH) treatment drug dutasteride, a 5α-reductase (5AR) inhibitor, is well known to reduce prostate carcinogenesis and PSA.[6] 5AR inhibitors block the conversion of testosterone to 5‐α‐dihydrotestosterone, which induces prostate epithelial cell proliferation. Here, KLK3 is linked to benign prostatic hyperplasia.